Bogart v. King Pharm

CourtCourt of Appeals for the Third Circuit
DecidedJuly 16, 2007
Docket06-2098
StatusPublished

This text of Bogart v. King Pharm (Bogart v. King Pharm) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bogart v. King Pharm, (3d Cir. 2007).

Opinion

Opinions of the United 2007 Decisions States Court of Appeals for the Third Circuit

7-16-2007

Bogart v. King Pharm Precedential or Non-Precedential: Precedential

Docket No. 06-2098

Follow this and additional works at: http://digitalcommons.law.villanova.edu/thirdcircuit_2007

Recommended Citation "Bogart v. King Pharm" (2007). 2007 Decisions. Paper 661. http://digitalcommons.law.villanova.edu/thirdcircuit_2007/661

This decision is brought to you for free and open access by the Opinions of the United States Court of Appeals for the Third Circuit at Villanova University School of Law Digital Repository. It has been accepted for inclusion in 2007 Decisions by an authorized administrator of Villanova University School of Law Digital Repository. For more information, please contact Benjamin.Carlson@law.villanova.edu. PRECEDENTIAL

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT __________

No. 06-2098 __________

UNITED STATES OF AMERICA ex rel. EDWARD BOGART; EDWARD BOGART, individually; STATE OF ILLINOIS ex rel. EDWARD BOGART; STATE OF CALIFORNIA ex rel. EDWARD BOGART; STATE OF FLORIDA ex rel. EDWARD BOGART; STATE OF TEXAS ex rel. EDWARD BOGART; STATE OF MASSACHUSETTS ex rel. EDWARD BOGART; STATE OF TENNESSEE ex rel. EDWARD BOGART; STATE OF DELAWARE ex rel. EDWARD BOGART; STATE OF NEVADA ex rel. EDWARD BOGART;

(cont’d) STATE OF LOUISIANA ex rel. EDWARD BOGART; STATE OF HAWAII ex rel. EDWARD BOGART; DISTRICT OF COLUMBIA ex rel. EDWARD BOGART; STATE OF VIRGINIA ex rel. EDWARD BOGART; STATE OF NEW MEXICO ex rel. EDWARD BOGART

v.

KING PHARMACEUTICALS; MONARCH PHARMACEUTICALS; WYETH PHARMACEUTICALS; AMERICAN SERVICE GROUP; PRISON HEALTH SERVICES

Edward Bogart, Appellant __________

On Appeal from the United States District Court for the Eastern District of Pennsylvania (D.C. Civil No. 03-cv-01538) District Judge: Hon. Marvin Katz __________

2 Argued on May 8, 2007

Before: RENDELL and JORDAN, Circuit Judges, and VANASKIE,* District Judge

(Filed: July 16, 2007)

Samuel L. Boyd Boyd & Associates 6440 North Central Expressway, #600 Dallas, TX 75206

Carl A. Solano [ARGUED] Jennifer J. Nestle Schnader Harrison Segal & Lewis 1600 Market Street, Suite 3600 Philadelphia, PA 19103

Timothy K. Lewis Schnader Harrison Segal & Lewis Suite 300 2001 Pennsylvania Avenue, NW Washington, DC 20006 (cont’d)

* The Honorable Thomas I. Vanaskie, United States District Judge for the Middle District of Pennsylvania, sitting by designation.

3 Joel M. Androphy Berg & Androphy 3704 Travis Houston, TX 77002

Counsel for Appellant Edward Bogart

Michael T. Reynolds [ARGUED] Cravath, Swaine & Moore 825 Eighth Avenue Worldwide Plaza New York, NY 10019

John G. Harkins, Jr. Eleanor M. Illoway David W. Angstrom Harkins Cunningham 2005 Market Street 2800 One Commerce Square Philadelphia, Pa 19103

Counsel for Appellees King Pharmaceuticals; Monarch Pharmaceuticals

(cont’d)

4 Guy W. Horsley, Jr. [ARGUED] Office of Attorney General of Virginia 900 East Main Street Richmond, VA 243219

Counsel for Appellee State of Virginia

__________

OPINION __________

VANASKIE, District Judge.

Appellant/Relator Edward Bogart (“Bogart”) commenced this qui tam litigation on behalf of the United States, the District of Columbia, and ten states with qui tam legislation.1 Appellees King Pharmaceuticals and Monarch Pharmaceuticals

1 “Qui tam is short for ‘qui tam pro domino rege quam pro se ipso in hac parte sequitur,’ which means ‘who pursues this action on our Lord the King's behalf as well as his own.’” Rockwell Int’l Corp. v. United States, 127 S. Ct. 1397, 1402 n.2 (2007).

5 (collectively, “King”) ultimately settled the claims of the jurisdictions with qui tam statutes, and Bogart was paid counsel fees and expenses of approximately $800,000, plus relator fees in excess of $9 million. King also entered into settlement agreements with the nearly 40 States without qui tam legislation who were not parties to this case. Contending that his efforts produced settlements totaling more than $30 million for the non-qui tam States, Bogart unsuccessfully argued in the District Court that he was entitled to be paid up to one-third of that amount as attorneys’ fees under a common fund theory of recovery. He has appealed the District Court’s ruling. Finding no merit in Bogart’s contentions, we will affirm the District Court.

I

On March 12, 2003, Bogart commenced a qui tam action against King under the False Claims Act (“FCA”), 31 U.S.C. §§ 3729-3732.2 He also asserted claims on behalf of ten states and the District of Columbia that had statutes similar to the FCA, seeking a relator’s share and attorneys’ fees under these

2 The FCA authorizes private individuals to bring claims in the name of the United States to recover for alleged false or fraudulent claims submitted for payment to the United States. 31 U.S.C. § 3730(b)(1).

6 statutes as well.3 Bogart, a former employee of King, alleged that King misrepresented pricing information it supplied to the federal and state governments as a condition of its participation in various Medicaid programs.

Bogart filed amended complaints on July 1, 2003, and June 17, 2004, to assert claims on behalf of Appellee Virginia and New Mexico, respectively, which had recently enacted false claims statutes. In accordance with the FCA, the original complaint and the amended complaints were filed under seal.

At the time Bogart filed the second amended complaint, the United States permitted notification to the qui tam States of this litigation. Bogart was also permitted to notify the National Association of Medicaid Fraud Control Units (“NAMFCU”), an association of state attorney general offices that coordinates interstate efforts to prosecute Medicaid fraud claims

After notice of this lawsuit, the NAMFCU formed a committee to negotiate a settlement with King on behalf of its members, many of whom did not have qui tam statutes and were not parties to this litigation. Each state individually negotiated with King as well. Bogart did not participate in these settlement discussions.

3 The ten states were California, Delaware, Florida, Hawaii, Illinois, Louisiana, Massachusetts, Nevada, Tennessee, and Texas.

7 On September 22, 2004, in anticipation of impending settlements, Bogart filed a Third Amended Complaint, asserting a request for “Common Fund Relief” with respect to amounts recovered by non-qui tam jurisdictions. In Paragraph 221 of the Third Amended Complaint, Bogart asserted:

While the states possessing qui tam statutes have a regulatory scheme for rewarding the Relator for coming forward, those which have none will potentially receive a windfall with little or no investigation or commitment of time or resources to the recovery. The Common Fund doctrine preserves the right of the litigant or counsel to an award from the Common Fund generated.

Bogart sought recovery of up to one-third of the purported common fund, although he did not specify whether this percentage represented a relator’s share or counsel fees.

On October 31, 2005, the United States, the States, and King announced an aggregate settlement of $124,057,318. Of this amount, $73,420,225 was payable to the United States; $20,239,317 was payable to the qui tam States; and $30,397,776 was payable to the non-qui tam States. Bogart did not participate in the negotiation of the settlements and was not a party to any of the settlement agreements.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Trustees v. Greenough
105 U.S. 527 (Supreme Court, 1882)
Boeing Co. v. Van Gemert
444 U.S. 472 (Supreme Court, 1980)
Rockwell International Corp. v. United States
549 U.S. 457 (Supreme Court, 2007)
In Re SmithKline Beckman Corp. Securities Litigation
751 F. Supp. 525 (E.D. Pennsylvania, 1990)
In Re DN Associates
165 B.R. 344 (D. Maine, 1994)
United States Ex Rel. Bogart v. King Pharmaceuticals
410 F. Supp. 2d 404 (E.D. Pennsylvania, 2006)
United States Ex Rel. Merena v. Smithkline Beecham Corp.
52 F. Supp. 2d 420 (E.D. Pennsylvania, 1998)
Savoie v. Merchants Bank
84 F.3d 52 (Second Circuit, 1996)
Vincent v. Hughes Air West, Inc.
557 F.2d 759 (Ninth Circuit, 1977)

Cite This Page — Counsel Stack

Bluebook (online)
Bogart v. King Pharm, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bogart-v-king-pharm-ca3-2007.